Clinical trials sponsored by MediLink Therapeutics (Suzhou) Co., Ltd.

Phase breakdown

Conditions studied

Recruiting trials led by MediLink Therapeutics (Suzhou) Co., Ltd.

• A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC
  NCT06439771 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC
  NCT06241846 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 24 locations
• A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
  NCT07407933 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 22 locations
• A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer
  NCT07739758 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
  NCT07169994 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 20 locations
• A Study of YL202 in Selected Patients With Advanced Solid Tumors
  NCT06107686 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 82 locations

Common questions

How many trials is MediLink Therapeutics (Suzhou) Co., Ltd. recruiting for?

MediLink Therapeutics (Suzhou) Co., Ltd. is the lead sponsor of 6 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.